Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

Common principles and intermediates of viral protein-mediated fusion: the HIV-1 paradigm.

Melikyan GB.

Retrovirology. 2008 Dec 10;5:111. doi: 10.1186/1742-4690-5-111. Review.

2.

Viral membrane fusion.

Harrison SC.

Nat Struct Mol Biol. 2008 Jul;15(7):690-8. doi: 10.1038/nsmb.1456. Review.

3.

Impact of the enfuvirtide resistance mutation N43D and the associated baseline polymorphism E137K on peptide sensitivity and six-helix bundle structure.

Bai X, Wilson KL, Seedorff JE, Ahrens D, Green J, Davison DK, Jin L, Stanfield-Oakley SA, Mosier SM, Melby TE, Cammack N, Wang Z, Greenberg ML, Dwyer JJ.

Biochemistry. 2008 Jun 24;47(25):6662-70. doi: 10.1021/bi702509d.

PMID:
18507398
4.

Selection of T1249-resistant human immunodeficiency virus type 1 variants.

Eggink D, Baldwin CE, Deng Y, Langedijk JP, Lu M, Sanders RW, Berkhout B.

J Virol. 2008 Jul;82(13):6678-88. doi: 10.1128/JVI.00352-08. Epub 2008 Apr 23.

5.

Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor.

He Y, Xiao Y, Song H, Liang Q, Ju D, Chen X, Lu H, Jing W, Jiang S, Zhang L.

J Biol Chem. 2008 Apr 25;283(17):11126-34. doi: 10.1074/jbc.M800200200. Epub 2008 Feb 26.

6.

HIV-1 envelope glycoprotein-mediated fusion and pathogenesis: implications for therapy and vaccine development.

Jacobs A, Garg H, Viard M, Raviv Y, Puri A, Blumenthal R.

Vaccine. 2008 Jun 6;26(24):3026-35. doi: 10.1016/j.vaccine.2007.12.026. Epub 2008 Jan 10.

7.

Evolution of genotypic and phenotypic resistance during chronic treatment with the fusion inhibitor T-1249.

Melby T, Demasi R, Cammack N, Miralles GD, Greenberg ML.

AIDS Res Hum Retroviruses. 2007 Nov;23(11):1366-73. doi: 10.1089/aid.2006.0277.

PMID:
18184079
8.

T-20 and T-1249 HIV fusion inhibitors' structure and conformation in solution: a molecular dynamics study.

Martins Do Canto AM, Palace Carvalho AJ, Prates Ramalho JP, Loura LM.

J Pept Sci. 2008 Apr;14(4):442-7.

PMID:
18069719
9.

HADDOCK versus HADDOCK: new features and performance of HADDOCK2.0 on the CAPRI targets.

de Vries SJ, van Dijk AD, Krzeminski M, van Dijk M, Thureau A, Hsu V, Wassenaar T, Bonvin AM.

Proteins. 2007 Dec 1;69(4):726-33.

PMID:
17803234
10.

Molecular determinants of antiviral potency of paramyxovirus entry inhibitors.

Porotto M, Carta P, Deng Y, Kellogg GE, Whitt M, Lu M, Mungall BA, Moscona A.

J Virol. 2007 Oct;81(19):10567-74. Epub 2007 Jul 25.

11.

Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.

Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK.

Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. Epub 2007 Jul 19.

12.
13.

HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides.

Liu S, Jing W, Cheung B, Lu H, Sun J, Yan X, Niu J, Farmar J, Wu S, Jiang S.

J Biol Chem. 2007 Mar 30;282(13):9612-20. Epub 2007 Feb 2.

14.

Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment.

Aquaro S, D'Arrigo R, Svicher V, Perri GD, Caputo SL, Visco-Comandini U, Santoro M, Bertoli A, Mazzotta F, Bonora S, Tozzi V, Bellagamba R, Zaccarelli M, Narciso P, Antinori A, Perno CF.

J Antimicrob Chemother. 2006 Oct;58(4):714-22. Epub 2006 Aug 5.

PMID:
16891628
15.

Kinetic dependence to HIV-1 entry inhibition.

Steger HK, Root MJ.

J Biol Chem. 2006 Sep 1;281(35):25813-21. Epub 2006 Jun 27.

16.

Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2.

Melby T, Sista P, DeMasi R, Kirkland T, Roberts N, Salgo M, Heilek-Snyder G, Cammack N, Matthews TJ, Greenberg ML.

AIDS Res Hum Retroviruses. 2006 May;22(5):375-85.

PMID:
16706613
17.

Virus membrane-fusion proteins: more than one way to make a hairpin.

Kielian M, Rey FA.

Nat Rev Microbiol. 2006 Jan;4(1):67-76. Review.

PMID:
16357862
18.

Design and characterization of viral polypeptide inhibitors targeting Newcastle disease virus fusion.

Zhu J, Jiang X, Liu Y, Tien P, Gao GF.

J Mol Biol. 2005 Dec 2;354(3):601-13. Epub 2005 Oct 10.

PMID:
16253271
19.

Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro.

Mink M, Mosier SM, Janumpalli S, Davison D, Jin L, Melby T, Sista P, Erickson J, Lambert D, Stanfield-Oakley SA, Salgo M, Cammack N, Matthews T, Greenberg ML.

J Virol. 2005 Oct;79(19):12447-54.

20.

Effect of naturally-occurring gp41 HR1 variations on susceptibility of HIV-1 to fusion inhibitors.

Chinnadurai R, Münch J, Kirchhoff F.

AIDS. 2005 Sep 2;19(13):1401-5.

PMID:
16103771

Supplemental Content

Support Center